<SEC-DOCUMENT>0001157523-21-000816.txt : 20210622
<SEC-HEADER>0001157523-21-000816.hdr.sgml : 20210622
<ACCEPTANCE-DATETIME>20210622082834
ACCESSION NUMBER:		0001157523-21-000816
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20210622
FILED AS OF DATE:		20210622
DATE AS OF CHANGE:		20210622

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ImmunoPrecise Antibodies Ltd.
		CENTRAL INDEX KEY:			0001715925
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39530
		FILM NUMBER:		211033112

	BUSINESS ADDRESS:	
		STREET 1:		880 - 580 HORNBY STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C3B6
		BUSINESS PHONE:		6048060626

	MAIL ADDRESS:	
		STREET 1:		880 - 580 HORNBY STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C3B6
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a52449184.htm
<DESCRIPTION>IMMUNOPRECISE ANTIBODIES LTD. 6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: business wire
         Document created using EDGARfilings PROfile 7.5.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div>&#160; <br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
      <div style="font-weight: bold;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">FORM 6-K</div>
      <div style="font-weight: bold;">&#160;</div>
      <div style="text-align: center; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
      <div style="text-align: center; font-weight: bold;">PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
      <div style="text-align: center; font-weight: bold;">&#160;</div>
      <div style="text-align: center;">For the month of June 2021</div>
      <div style="text-align: center;">&#160;</div>
      <div style="text-align: center;">Commission File Number: <font style="font-weight: bold;">001-39530</font></div>
      <div>&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">ImmunoPrecise Antibodies Ltd.</div>
      <div style="text-align: center;">(Translation of registrant&#8217;s name into English)</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8</div>
      <div style="text-align: center;">(Address of principal executive office)</div>
      <div>&#160;</div>
      <div style="text-align: justify;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
      <div><br>
      </div>
      <div style="text-align: center;">Form 20-F&#160; <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font> Form 40-F&#160; <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font></div>
      <div style="text-align: justify;">&#160;</div>
      <div style="text-align: justify;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
      <div style="text-align: justify;">&#160;</div>
      <div style="text-align: justify;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
      <div style="text-align: justify;">&#160;</div>
      <div style="text-align: justify;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
      <div>
        <div style="font-family: 'Times New Roman', serif; font-size: 1pt;">&#160;</div>
      </div>
      <div style="text-align: justify;">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="margin-top: 6pt; font-size: 12pt;">&#160;</div>
      <div style="text-align: center;"><font style="font-weight: bold;">EXHIBIT INDEX</font></div>
      <div style="text-align: center;">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="ze5c7d3bee10542d2aa67507cda698a09" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 11%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-weight: bold;">Exhibit No.</div>
            </td>
            <td style="width: 1.54%; vertical-align: bottom;">
              <div>&#160;</div>
            </td>
            <td style="width: 86.92%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="font-weight: bold;">Description</div>
            </td>
          </tr>
          <tr>
            <td style="width: 11%; vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif;"><a href="a52449184_ex991.htm">99.1</a></div>
            </td>
            <td style="width: 1.54%; vertical-align: bottom;">
              <div>&#160;</div>
            </td>
            <td style="width: 86.92%; vertical-align: bottom;">
              <div style="text-align: justify;"><a href="a52449184_ex991.htm">Press Release dated
                  June 22, 2021.</a></div>
            </td>
          </tr>

      </table>
      <div style="text-align: center;">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="margin-top: 6pt; font-size: 12pt;">&#160;</div>
      <div style="text-align: center; margin-top: 6pt; font-weight: bold;">SIGNATURE</div>
      <div style="text-align: center; font-weight: bold;">&#160;</div>
      <div style="text-align: justify; text-indent: 24pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
        behalf by the undersigned, thereunto duly authorized.</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z5ad99cb046bc4adb9af7b92549b323e4" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div>&#160;</div>
            </td>
            <td style="vertical-align: top;" colspan="2">
              <div style="font-weight: bold;">IMMUNOPRECISE ANTIBODIES LTD.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top;">
              <div>&#160;</div>
            </td>
            <td style="width: 47%; vertical-align: top;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div>Date: June 22, 2021</div>
            </td>
            <td style="width: 3%; vertical-align: top;">
              <div>By:</div>
            </td>
            <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-style: italic;">/s/ Lisa Helbling</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top;">
              <div>&#160;</div>
            </td>
            <td style="width: 47%; vertical-align: top;">
              <div>Lisa Helbling</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top;">
              <div>&#160;</div>
            </td>
            <td style="width: 47%; vertical-align: top;">
              <div>Chief Financial Officer</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify;">&#160;</div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a52449184_ex991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: business wire
         Document created using EDGARfilings PROfile 7.5.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <div style="text-align: right;"><font style="font-weight: bold;"> <br>
    </font></div>
  <div>
    <div class="bw-release">
      <h1 style="text-align: center; list-style-position: inside;FONT-SIZE: 14pt;"> <b>Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform</b> </h1>
      <div class="bw-release-body">
        <div class="bw-release-table-js bw-release-story">
          <p>VICTORIA, British Columbia--(BUSINESS WIRE)--June 22, 2021--IMMUNOPRECISE ANTIBODIES LTD (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) the market leader in full-service therapeutic discovery and development and Eurofins Discovery,
            the leading provider of products and services to the drug discovery industry and a Eurofins Scientific (Paris:ERF) company, announced a commercial collaboration. Leveraging complementary strengths in Eurofins Discovery&#8217;s in vitro pharmacology
            services and ImmunoPrecise&#8217;s in vivo characterization and discovery technologies, this collaboration provides greater access to solutions that empower scientists to pursue life-changing medicines in a diverse range of indications. </p>
          <p> Eurofins Discovery&#8217;s global clients will have access to ImmunoPrecise&#8217;s end-to-end antibody discovery capabilities using wild type and best-in-class in vivo antibody discovery technologies that are optimized to deeply mine antibody
            repertoires. This collaboration supports Eurofins Discovery&#8217;s biotherapeutics strategy to extend their capacity and capability to develop new biologic entities, guiding clients from target validation through preclinical development, production,
            and beyond with the expertise required to address the unique challenges of each discovery project. </p>
          <p> As the leading global innovation-driven and customer-focused providers, Eurofins Discovery and ImmunoPrecise share common values in the culture of collaboration and the unrelenting pursuit of service excellence. </p>
          <p> <b>For further information</b> </p>
          <p> www.eurofinsdiscoveryservices.com </p>
          <p> <b>About Eurofins Discovery</b> </p>
          <p> Eurofins Discovery has supported Drug Discovery research for over 40 years. Eurofins is recognized as the industry leader for providing drug discovery researchers the largest and most diverse portfolio of standard and custom in vitro safety
            &amp; pharmacology assays and panels for drug screening and profiling. In addition to in vitro safety pharmacology strengths, we also offer a broad portfolio of over 3500 drug discovery services and 1800 products. These include in vitro assays,
            cell-based phenotypic assays, safety pharmacology and efficacy, ADME toxicology, medicinal chemistry design, synthetic chemistry, and custom proteins and assay development capabilities. We support a variety of drug discovery targets such as
            GPCRs, Kinases, Ion Channels, Nuclear Hormone Receptors and other proteins &amp; enzymes. The Eurofins Discovery capabilities, expertise, knowledge and skill sets enable the company to provide clients the benefit of being able to work with a
            single outsourcing provider (CRO) for all their drug discovery programs. </p>
          <p> <b>About Eurofins &#8211; the global leader in bio-analysis</b> </p>
          <p> Eurofins is Testing for Life. Eurofins is the global leader in food, environment, and pharmaceutical product testing. It is also one of the market leaders in testing and laboratory services for genomics, discovery pharmacology, forensics,
            advanced material sciences and has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing. </p>
          <p> With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins&#8217; companies offer a portfolio of over 200,000 analytical methods. </p>
          <p> Eurofins Shares are listed on Euronext Paris Stock Exchange. </p>
          <p> <b>About ImmunoPrecise Antibodies</b> </p>
          <p> ImmunoPrecise is an innovation-driven technology platform company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of classes of disease targets. The Company aims to transform
            the conventional multi-vendor antibody discovery model by providing a comprehensive suite of services tailored to optimize antibody genetic diversity and epitope coverage, to discover antibodies against rare and/or challenging epitopes. For
            further information, visit www.immunoprecise.com or contact solutions@immunoprecise.com. </p>
        </div>
        <div class="bw-release-contact">
          <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
          <p> Media: <br>
            Aida Yodites, Director Marketing Communications <br>
            AidaYodites@eurofinsus.com </p>
          <p> Investors: <br>
            LifeSci Advisors <br>
            John Mullaly <br>
            Email: jmullaly@lifesciadvisors.com </p>
        </div>
      </div>
    </div>
    <font style="font-weight: bold;"> </font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
